Skip to main content

Table 2 Laboratory findings at baseline and after TACE

From: Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization

Laboratory findings Baseline, Mean ± SD Post-TACE, Mean ± SD p-value
Total bilirubin (mg/dL) 1.03 ± 0.61 1.17 ± 0.86 0.027*
AST (U/L) 77.20 ± 51.65 73.69 ± 57.05 0.59
ALT (U/L) 56.21 ± 38.35 52.48 ± 43.95 0.300
Albumin (g/dL) 3.50 ± 0.57 3.20 ± 0.56 <0.001*
INR 1.16 ± 0.13 1.20 ± 0.13 <0.001*
Platelet (× 103/µL) 167.46 ± 107.53 169.58 ± 116.82 0.62
Creatinine (mg/dL) 0.89 ± 0.36 0.88 ± 0.68 0.93
AFP (ng/mL) 3460.38 ± 14382.67 2449.96 ± 8.177.59 0.85
  1. AFP Alpha fetoprotein, ALT Alanine aminotransferase, AST Aspartate aminotransferase, INR International normalized ratio, mg/dL Milligram per deciliter; ng/mL, Nanogram per milliliter; SD Standard deviation, TACE Trans-arterial chemoembolization, U/L Units per liter, µL Microliter
  2. *p-value ≤ 0.05